Carboplatin
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 100130

CAS#: 41575-94-4

Description: Carboplatin is a second-generation platinum compound with a broad spectrum of antineoplastic properties. Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue. This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.


Chemical Structure

img
Carboplatin
CAS# 41575-94-4

Theoretical Analysis

MedKoo Cat#: 100130
Name: Carboplatin
CAS#: 41575-94-4
Chemical Formula: C6H12N2O4Pt
Exact Mass: 0.00
Molecular Weight: 371.250
Elemental Analysis: C, 19.41; H, 3.26; N, 7.55; O, 17.24; Pt, 52.55

Price and Availability

Size Price Availability Quantity
25mg USD 90 Ready to ship
50mg USD 150 Ready to ship
100mg USD 225 Ready to ship
200mg USD 385 Ready to ship
500mg USD 650 Ready to ship
1g USD 1150 Ready to ship
Bulk inquiry

Synonym: Carboplatin Hexal; Carboplatino; US brand names: Paraplat; Paraplatin; Foreign brand names: Blastocarb; Carboplat; Carbosin; Carbosol; Carbotec; Displata; Ercar; Nealorin; Novoplatinum; Paraplatin AQ; Paraplatine; Platinwas; Ribocarbo; Abbreviation: CBDCA Code name: JM8

IUPAC/Chemical Name: platinum, diammine [1,1-cyclobutane-dicarboxylato(2-)-0,0’]-,(SP-4-2)

InChi Key: OLESAACUTLOWQZ-UHFFFAOYSA-L

InChi Code: InChI=1S/C6H8O4.2H3N.Pt/c7-4(8)6(5(9)10)2-1-3-6;;;/h1-3H2,(H,7,8)(H,9,10);2*1H3;/q;;;+2/p-2

SMILES Code: [O-]C(C1(CCC1)C([O-])=O)=O.[Pt+2].N.N

Appearance: white solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in water at 5 mg / mL

Shelf Life: >10 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2931.90.9051

More Info: History Carboplatin was discovered and developed at the Institute of Cancer Research in London. Bristol-Myers Squibb gained Food and Drug Administration (FDA) approval for carboplatin, under the brand name Paraplatin, in March 1989. Starting in October 2004, generic versions of the drug became available. From: http://en.wikipedia.org/wiki/Carboplatin .   DRUG DESCRIPTION PARAPLATIN® (carboplatin aqueous solution) INJECTION is supplied as a sterile, pyrogen-free, 10 mg/mL aqueous solution of carboplatin. Carboplatin is a platinum coordination compound. Carboplatin is a crystalline powder with the molecular formula of C6H12N2O4Pt and a molecular weight of 371.25. It is soluble in water at a rate of approximately 14 mg/mL, and the pH of a 1% solution is 5 to 7. It is virtually insoluble in ethanol, acetone, and dimethylacetamide.   CLINICAL PHARMACOLOGY Carboplatin, like cisplatin, produces predominantly interstrand DNA cross-links rather than DNA-protein cross-links. This effect is apparently cell-cycle nonspecific. The aquation of carboplatin, which is thought to produce the active species, occurs at a slower rate than in the case of cisplatin. Despite this difference, it appears that both carboplatin and cisplatin induce equal numbers of drug-DNA cross-links, causing equivalent lesions and biological effects. The differences in potencies for carboplatin and cisplatin appear to be directly related to the difference in aquation rates. In patients with creatinine clearances of about 60 mL/min or greater, plasma levels of intact carboplatin decay in a biphasic manner after a 30-minute intravenous infusion of 300 mg/m2 to 500 mg/m2 of carboplatin. The initial plasma half-life (alpha) was found to be 1.1 to 2 hours (n=6), and the postdistribution plasma half-life (beta) was found to be 2.6 to 5.9 hours (n=6). The total body clearance, apparent volume of distribution and mean residence time for carboplatin are 4.4 L/hour, 16 L and 3.5 hours, respectively. The Cmax values and areas under the plasma concentration versus time curves from 0 to infinity (AUC inf) increase linearly with dose, although the increase was slightly more than dose proportional. Carboplatin, therefore, exhibits linear pharmacokinetics over the dosing range studied (300 mg/m2 to 500 mg/m2). Carboplatin is not bound to plasma proteins. No significant quantities of protein-free, ultrafilterable platinum-containing species other than carboplatin are present in plasma. However, platinum from carboplatin becomes irreversibly bound to plasma proteins and is slowly eliminated with a minimum half-life of 5 days. The major route of elimination of carboplatin is renal excretion. Patients with creatinine clearances of approximately 60 mL/min or greater excrete 65% of the dose in the urine within 12 hours and 71% of the dose within 24 hours. All of the platinum in the 24-hour urine is present as carboplatin. Only 3% to 5% of the administered platinum is excreted in the urine between 24 and 96 hours. There are insufficient data to determine whether biliary excretion occurs.   Recent review papers on Carboplatin 1: Ando Y, Shimokata T, Yasuda Y, Hasegawa Y. Carboplatin dosing for adult Japanese patients. Nagoya J Med Sci. 2014 Feb;76(1-2):1-9. Review. PubMed PMID: 25129986. 2: Pandey A, Bhosale B, Pandita V, Singh A, Ghosh J, Ghosh J, Bajpai J. Carboplatin hypersensitivity in relapsed ovarian carcinoma: A therapeutic challenge. Indian J Med Paediatr Oncol. 2014 Jan;35(1):17-20. doi: 10.4103/0971-5851.133705. Review. PubMed PMID: 25006278; PubMed Central PMCID: PMC4080656. 3: Kimura H, Uegaki M, Aoyama T, Kawai J, Hamano T, Hashimura T. [Carboplatin plus irinotecan induced partial response in a patient with small cell carcinoma of the prostate; a case report]. Hinyokika Kiyo. 2014 Jan;60(1):39-43. Review. Japanese. PubMed PMID: 24594772. 4: Lorusso D, Petrelli F, Coinu A, Raspagliesi F, Barni S. A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer. Gynecol Oncol. 2014 Apr;133(1):117-23. doi: 10.1016/j.ygyno.2014.01.042. Epub 2014 Jan 31. Review. PubMed PMID: 24486604. 5: Watanabe K, Shinkai M, Goto H, Yoshikawa S, Yamaguchi N, Hara Y, Shinoda M, Moriyama Y, Rubin BK, Ishigatsubo Y, Kaneko T. Chemotherapy with carboplatin and paclitaxel after failure of primary chemotherapy for advanced thymic carcinoma. A report of three cases and review of the literature. Tumori. 2013 Jul-Aug;99(4):e172-6. doi: 10.1700/1361.15119. Review. PubMed PMID: 24326856. 6: Otsuka I, Takaya H, Takagi K, Tanaka A, Kaseki H, Izuta C, Sato M, Matsuura T, Suzuki Y. [Carcinosarcoma of the ovary treated with paclitaxel and carboplatin chemotherapy - a report of 4 cases]. Gan To Kagaku Ryoho. 2013 Sep;40(9):1249-53. Review. Japanese. PubMed PMID: 24047791. 7: de Castria TB, da Silva EM, Gois AF, Riera R. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer. Cochrane Database Syst Rev. 2013 Aug 16;8:CD009256. doi: 10.1002/14651858.CD009256.pub2. Review. PubMed PMID: 23949842. 8: Ding Q, Zhan J. Amrubicin: potential in combination with cisplatin or carboplatin to treat small-cell lung cancer. Drug Des Devel Ther. 2013 Aug 1;7:681-9. doi: 10.2147/DDDT.S41910. eCollection 2013. Review. PubMed PMID: 23946645; PubMed Central PMCID: PMC3738252. 9: Ashur-Fabian O, Blumenthal DT, Bakon M, Nass D, Davis PJ, Hercbergs A. Long-term response in high-grade optic glioma treated with medically induced hypothyroidism and carboplatin: a case report and review of the literature. Anticancer Drugs. 2013 Mar;24(3):315-23. doi: 10.1097/CAD.0b013e32835c7a47. Review. PubMed PMID: 23348245. 10: Shaikh F, Nathan PC, Hale J, Uleryk E, Frazier L. Is there a role for carboplatin in the treatment of malignant germ cell tumors? A systematic review of adult and pediatric trials. Pediatr Blood Cancer. 2013 Apr;60(4):587-92. doi: 10.1002/pbc.24288. Epub 2012 Sep 13. Review. PubMed PMID: 22976789.           Contact MedKoo: Tel: 919-636-5577 Fax: 919-980-4831 Email: sales@medkoo.com @import url(http://www.google.com/cse/api/branding.css); .style23 { text-align: left; } .style25 { margin-left: 10px; margin-right: 10px; } .style58 { font-size: xx-large; text-align: left; margin-left: 10px; margin-right: 10px; } .style60 { font-size: medium; text-align: left; margin-left: 10px; margin-right: 10px; } .style61 { font-family: serif; font-size: medium; border-collapse: separate; border-color: #FF0000; border-width: 1px; } .style62 { margin-left: 10px; margin-right: 10px; color: #FF0000; font-size: medium; } .style65 { font-family: "Times New Roman", Times, serif; text-align: right; font-size: medium; } .style66 { font-size: medium; text-align: right; margin-left: 10px; margin-right: 10px; } .style69 { text-align: right; margin-right: 10px; margin-left: 10px; } .style70 { line-height: 200%; margin-left: 10px; margin-right: 10px; } .style71 { margin-left: 10px; margin-right: 10px; color: #000000; font-size: medium; } .style72 { margin-left: 10px; margin-right: 10px; font-size: small; } .style74 { margin-left: 10px; margin-right: 10px; color: #FFFFFF; font-size: medium; } .style76 { line-height: 200%; margin-left: 10px; margin-right: 10px; color: #FF0000; } .style77 { color: #FFFFFF; } .style78 { font-size: 10.0pt; font-family: "Times New Roman", serif; border: 1.0pt solid red; } .style79 { border-width: 0; } .style80 { border-width: 0; font-size: medium; } .style81 { margin-left: 10px; margin-right: 10px; font-size: x-large; color: #0000FF; } .style83 { font-size: x-large; }   google.load('search', '1'); google.setOnLoadCallback(function() { google.search.CustomSearchControl.attachAutoCompletion( '009260295461932489120:6tlieyglhri', document.getElementById('q'), 'cse-search-box'); }); (Keyword; CAS#; MedKoo Cat#)               About us   |  Services   |  Products   |  News   |  Careers   |  Contact us © MedKoo Biosciences. All Rights Reserved   var _gaq = _gaq || []; _gaq.push(['_setAccount', 'UA-18061634-1']); _gaq.push(['_trackPageview']); (function() { var ga = document.createElement('script'); ga.type = 'text/javascript'; ga.async = true; ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js'; var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(ga, s); })();

Biological target: DNA synthesis inhibitor which binds to DNA, inhibits replication and transcription and induces cell death.
In vitro activity: The results show that spheroid formation of EOC cell lines is significantly faster and more uniform in polydimethylsiloxane (PDMS) microfluidic devices and Matrigel-assisted ULA plates than in hanging-droplets or ULA plates without Matrigel. Carboplatin responses were observed in both 3D spheroid models using flow cytometric analysis, but no significant decrease in spheroid size was detected. For the majority of the EOC cell lines (3 out of 4) a similar response to carboplatin treatment was observed by both spheroid methods. Interestingly, two cell lines classified as resistant to carboplatin in 2D cultures responded as sensitive in 3D models, and one sensitive cell line in 2D culture showed resistance in the 3D spheroids. The results highlight the challenges in choosing appropriate pre-clinical models for empirical drug testing. Reference: PLoS One. 2020; 15(12): e0244549. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7774933/
In vivo activity: Importantly, when replacing Cis with another lower nephrotoxicity platinum-based chemotherapeutic agent, Carboplatin, we found Carboplatin could still degrade ARv7 (and fAR) (Fig. 1g), before induction of apoptosis (Fig.2l2l). Together, the results shown in Fig. 1a–g suggest that Cis and Carboplatin may degrade ARv7 and AR mutants of AR-F876L at low doses that have minimal effects on the induction of apoptosis in multiple EnzR CRPC cells. Reference: Cell Death Dis. 2020 Nov; 11(11): 942. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7606511/

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMF 1.0 2.69
Water 7.1 19.10
PBS (pH 7.2) 1.0 2.69

Preparing Stock Solutions

The following data is based on the product molecular weight 371.25 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol: 1. Patra B, Lateef MA, Brodeur MN, Fleury H, Carmona E, Péant B, Provencher D, Mes-Masson AM, Gervais T. Carboplatin sensitivity in epithelial ovarian cancer cell lines: The impact of model systems. PLoS One. 2020 Dec 31;15(12):e0244549. doi: 10.1371/journal.pone.0244549. PMID: 33382759; PMCID: PMC7774933. 2. Chou FJ, Lin C, Tian H, Lin W, You B, Lu J, Sahasrabudhe D, Huang CP, Yang V, Yeh S, Niu Y, Chang C. Preclinical studies using cisplatin/carboplatin to restore the Enzalutamide sensitivity via degrading the androgen receptor splicing variant 7 (ARv7) to further suppress Enzalutamide resistant prostate cancer. Cell Death Dis. 2020 Nov 2;11(11):942. doi: 10.1038/s41419-020-02970-4. PMID: 33139720; PMCID: PMC7606511.
In vitro protocol: 1. Patra B, Lateef MA, Brodeur MN, Fleury H, Carmona E, Péant B, Provencher D, Mes-Masson AM, Gervais T. Carboplatin sensitivity in epithelial ovarian cancer cell lines: The impact of model systems. PLoS One. 2020 Dec 31;15(12):e0244549. doi: 10.1371/journal.pone.0244549. PMID: 33382759; PMCID: PMC7774933.
In vivo protocol: 1. Chou FJ, Lin C, Tian H, Lin W, You B, Lu J, Sahasrabudhe D, Huang CP, Yang V, Yeh S, Niu Y, Chang C. Preclinical studies using cisplatin/carboplatin to restore the Enzalutamide sensitivity via degrading the androgen receptor splicing variant 7 (ARv7) to further suppress Enzalutamide resistant prostate cancer. Cell Death Dis. 2020 Nov 2;11(11):942. doi: 10.1038/s41419-020-02970-4. PMID: 33139720; PMCID: PMC7606511.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Friedrich M, Friedrich D, Kraft C, Rogmans C. Multimodal Treatment of Primary Advanced Ovarian Cancer. Anticancer Res. 2021 Jul;41(7):3253-3260. doi: 10.21873/anticanres.15111. Epub 2021 Jul 5. PMID: 34230119.

2: Eckert MA, Orozco C, Xiao J, Javellana M, Lengyel E. The Effects of Chemotherapeutics on the Ovarian Cancer Microenvironment. Cancers (Basel). 2021 Jun 23;13(13):3136. doi: 10.3390/cancers13133136. PMID: 34201616; PMCID: PMC8268261.

3: Kuo MT, Huang YF, Chou CY, Chen HHW. Targeting the Copper Transport System to Improve Treatment Efficacies of Platinum-Containing Drugs in Cancer Chemotherapy. Pharmaceuticals (Basel). 2021 Jun 8;14(6):549. doi: 10.3390/ph14060549. PMID: 34201235; PMCID: PMC8227247.

4: Oneda E, Abeni C, Zanotti L, Zaina E, Bighè S, Zaniboni A. Chemotherapy- induced neurotoxicity in the treatment of gynecological cancers: State of art and an innovative approach for prevention. World J Clin Oncol. 2021 Jun 24;12(6):458-467. doi: 10.5306/wjco.v12.i6.458. PMID: 34189069; PMCID: PMC8223716.

5: Zraik IM, Heß-Busch Y. Management von Nebenwirkungen der Chemotherapie und deren Langzeitfolgen [Management of chemotherapy side effects and their long- term sequelae]. Urologe A. 2021 Jul;60(7):862-871. German. doi: 10.1007/s00120-021-01569-7. Epub 2021 Jun 29. PMID: 34185118.

6: Kast J, Dutta S, Upreti VV. Panitumumab: A Review of Clinical Pharmacokinetic and Pharmacology Properties After Over a Decade of Experience in Patients with Solid Tumors. Adv Ther. 2021 Jul;38(7):3712-3723. doi: 10.1007/s12325-021-01809-4. Epub 2021 Jun 18. PMID: 34152568.

7: Jackisch C, Cortazar P, Geyer CE Jr, Gianni L, Gligorov J, Machackova Z, Perez EA, Schneeweiss A, Tolaney SM, Untch M, Wardley A, Piccart M. Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledge. Cancer Treat Rev. 2021 May 20;99:102229. doi: 10.1016/j.ctrv.2021.102229. Epub ahead of print. PMID: 34139476.

8: Boztepe T, Castro GR, León IE. Lipid, polymeric, inorganic-based drug delivery applications for platinum-based anticancer drugs. Int J Pharm. 2021 Jun 9;605:120788. doi: 10.1016/j.ijpharm.2021.120788. Epub ahead of print. PMID: 34116182.

9: Lv P, Man S, Xie L, Ma L, Gao W. Pathogenesis and therapeutic strategy in platinum resistance lung cancer. Biochim Biophys Acta Rev Cancer. 2021 Jun 4;1876(1):188577. doi: 10.1016/j.bbcan.2021.188577. Epub ahead of print. PMID: 34098035.

10: Daniels AB, Patel SN, Milam RW, Kohanim S, Friedman DL, Koyama T. Effect of Intravenous Chemotherapy Regimen on Globe Salvage Success Rates for Retinoblastoma Based on Disease Class-A Meta-Analysis. Cancers (Basel). 2021 May 6;13(9):2216. doi: 10.3390/cancers13092216. PMID: 34066325; PMCID: PMC8125212.

11: Cirri D, Bartoli F, Pratesi A, Baglini E, Barresi E, Marzo T. Strategies for the Improvement of Metal-Based Chemotherapeutic Treatments. Biomedicines. 2021 May 4;9(5):504. doi: 10.3390/biomedicines9050504. PMID: 34064364; PMCID: PMC8147839.

12: Toboni MD, Crane EK, Brown J, Shushkevich A, Chiang S, Slomovitz BM, Levine DA, Dowdy SC, Klopp A, Powell MA, Thaker PH. Uterine carcinosarcomas: From pathology to practice. Gynecol Oncol. 2021 Jul;162(1):235-241. doi: 10.1016/j.ygyno.2021.05.003. Epub 2021 May 21. PMID: 34030871.

13: Brandl A, Prabhu A. Intraperitoneal chemotherapy in the treatment of gastric cancer peritoneal metastases: an overview of common therapeutic regimens. J Gastrointest Oncol. 2021 Apr;12(Suppl 1):S32-S44. doi: 10.21037/jgo-2020-04. PMID: 33968424; PMCID: PMC8100714.

14: Sun T, Tian L, Guo Y, Zheng Y, Ouyang L, Zhang X, Lai Y, Yang G. Anaplastic carcinoma showing rhabdoid features combined with ovarian mucinous borderline cystadenoma: a case report and literature review. J Int Med Res. 2021 May;49(5):3000605211013159. doi: 10.1177/03000605211013159. PMID: 33951981; PMCID: PMC8113938.

15: Wang J, Liu Y, Liu N, Gao M, Yuan H. Paraneoplastic immunoglobulin A nephropathy in a patient with lung adenocarcinoma: A case report and literature review. J Int Med Res. 2021 Apr;49(4):300060521996868. doi: 10.1177/0300060521996868. PMID: 33926295; PMCID: PMC8113932.

16: Jagieła J, Bartnicki P, Rysz J. Nephrotoxicity as a Complication of Chemotherapy and Immunotherapy in the Treatment of Colorectal Cancer, Melanoma and Non-Small Cell Lung Cancer. Int J Mol Sci. 2021 Apr 28;22(9):4618. doi: 10.3390/ijms22094618. PMID: 33924827; PMCID: PMC8125622.

17: Chaft JE, Rimner A, Weder W, Azzoli CG, Kris MG, Cascone T. Evolution of systemic therapy for stages I-III non-metastatic non-small-cell lung cancer. Nat Rev Clin Oncol. 2021 Apr 28. doi: 10.1038/s41571-021-00501-4. Epub ahead of print. PMID: 33911215.

18: Serkies K, Baczkowska-Waliszewska Z. Adjuvant vaginal cuff brachytherapy in surgically treated endometrial carcinoma patients - in view of the recent evidence. J Contemp Brachytherapy. 2021 Apr;13(2):221-230. doi: 10.5114/jcb.2021.105291. Epub 2021 Apr 14. PMID: 33897797; PMCID: PMC8060967.

19: Hirte H, Poon R, Yao X, May T, Ethier JL, Petz L, Speakman J, Elit L. Neoadjuvant and adjuvant systemic therapy for newly diagnosed stage II- IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma: A systematic review. Crit Rev Oncol Hematol. 2021 Jun;162:103324. doi: 10.1016/j.critrevonc.2021.103324. Epub 2021 Apr 20. PMID: 33862245.

20: Farias JPF, Rangel da Silva MHC, Jácome AA. Emerging and Experimental Agents for Anal Cancer: What is New? J Exp Pharmacol. 2021 Apr 9;13:433-440. doi: 10.2147/JEP.S262342. PMID: 33859504; PMCID: PMC8043794.